Transparent INCY Forecast & Balanced News

Trade Smarter With AI models and Balanced News Summaries.


Correlated Stock Forecasts

Assets that tend to move strongly with INCY

JNJ Forecast   Johnson & Johnson (0.78)


LDOS Forecast   Leidos (0.7)


ABBV Forecast   Abbvie (0.66)


PPH Forecast   VanEck Pharmaceutical (0.65)


SCI Forecast   Service Corp. International (0.65)



Uncorrelated Stock Forecasts

Assets with little price relationship to INCY

KEY Forecast   Keycorp (0.0)


ICLN Forecast   BTC iShares Global Clean Energy (0.0)


AMAT Forecast   Applied Materials (0.0)


NKLA Forecast   Nikola (0.0)


COF Forecast   Capital One Financial (-0.0)



Anticorrelated Stock Forecasts

Assets that tend to move strongly against INCY

SOXS Forecast   Direxion Daily Semiconductor Bear 3X Shares (-0.46)


CRTO Forecast   Criteo (-0.49)


WMS Forecast   Advanced Drainage Systems (-0.5)


FL Forecast   Foot Locker (-0.51)


GTHX Forecast   G1 Therapeutics (-0.59)




INCY News over Time





Click points to explore news by date. News sentiment ranges from -10 (very negative) to +10 (very positive) where 0 is neutral.

Most Recent INCY News













Complement Helium's AI INCY Forecast with Balanced News and Deepen Your Understanding

FDA approves first at-home therapy for skin repigmentation in vitiligo patients

FDA approves first at-home therapy for skin repigmentation in vitiligo patients

health

The FDA announced the approval of Incyte’s ruxolitinib cream on Monday based on data collected from two duplicate Phase 3 clinical trials that found 30% of patients using the cream regained 75% or more skin repigmentation on the face and roughly 20% of patients regained at least 50% or more repigmentation on their body after 24 weeks.
STAT     Jul 19, 2022

Preliminary U.K. research says Lilly drug can reduce the risk of death among severely ill COVID-19 patients - MarketWatch

business

A new study found that baricitinib, a rheumatoid arthritis drug developed by Eli Lilly & Co. LLY, +1.64% and Incyte Corp. INCY, +0.85%, reduced the risk of death among patients who have been hospitalized with severe COVID-19. The new research, which was published Thursday in preprint form, meaning it's not peer-reviewed, came from the U.K.'s Recovery Trial. It compared baricitinib and the standard of care with the standard of care in about 8,000 patients over the course of 2021. Roche Holding AG's ROG, -1.72% arthritis drug tocilizumab has also been found to be an effective tool to reduce mortality risk among some severely ill COVID-19 patients.
Market Watch     Mar 04, 2022